Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Lett Appl Microbiol ; 73(2): 237-246, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33966285

ABSTRACT

Enterococcus species are present in the microbiota of humans and animals and have also been described in the environment. Among the species, Enterococcus faecium is one of the main pathogens associated with nosocomial infections worldwide. Enterococcus faecium isolates resistant to different classes of antimicrobials have been increasingly reported, including multidrug-resistant (MDR) isolates in environmental sources, which is worrying. Therefore, this study aimed to characterize E. faecium isolates obtained from soil and water samples regarding antimicrobial resistance and virulence determinants. A total 40 E. faecium isolates were recovered from 171 environmental samples. All isolates were classified as MDR, highlighting the resistance to the fluoroquinolones class, linezolid and vancomycin. Furthermore, high-level aminoglycoside resistance and high-level ciprofloxacin resistance were detected in some isolates. Several clinically relevant antimicrobial resistance genes were found, including vanC1, ermB, ermC, mefAE, tetM, tetL, ant(6')-Ia, ant(4')-Ia, aph(3')-IIIa and aac(6')-Ie-aph(2″)-Ia. Three virulence genes were detected among the MDR E. faecium isolates, such as esp, gelE and ace. The results of this study contribute to a better understanding of MDR E. faecium isolates carrying antimicrobial resistance and virulence genes in environmental sources and report for the first time in the world the presence of vanC1-producing E. faecium isolated from soil.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial/genetics , Enterococcus faecium/drug effects , Enterococcus faecium/genetics , Aminoglycosides/pharmacology , Ciprofloxacin/pharmacology , Cross Infection/microbiology , DNA, Bacterial , Enterococcus faecium/isolation & purification , Environmental Microbiology , Fluoroquinolones/pharmacology , Gram-Positive Bacterial Infections/epidemiology , Linezolid/pharmacology , Microbial Sensitivity Tests , Polymerase Chain Reaction , Prevalence , Vancomycin/pharmacology , Virulence , Virulence Factors/genetics
2.
Minerva Chir ; 70(6): 393-9, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25700151

ABSTRACT

AIM: The main purpose of our project was to evaluate the prevalence of lung cancer in high risk, asymptomatic individuals in addition to quantifying the rate of surgically resectable tumors, and evaluating the role of lung cancer with low dose computed tomography (LDCT) as a tool for lung cancer screening. METHODS: Between June 2011 and March 2014, 1500 volunteers at high risk for lung cancer were enrolled in our study and underwent LDCT in our institution. The subsequent diagnostic and therapeutic steps were planned in relation to the results emerging from LDCT. To evaluate speed and type of growth, solid nodules ≤4 mm were reassessed with annual LDCT, those >4-6 mm or >6-8 mm were reassessed with LDCT in 6 or 3 months while nodules suspicious for malignancy were investigated with PET-CT or biopsy according to NCCN guidelines. RESULTS: Non-calcified nodules were detected in 525 subjects (35% of population): among these 42% had a diameter ≤4 mm, 43% had a diameter >5 mm but <10 mm, 3% appeared as "ground glass" lesions, and 63 (12% of detected nodules) had malignant characteristics (irregular margins, retraction of the surrounding parenchyma, diameter >10 mm). Among the 63 patients who underwent PET-CT or biopsy, 25 cases resulted positive for lung cancer (1.7% of population). These patients underwent surgical treatment with histological detection of tumors in stages IA, IB or IIB. CONCLUSION: Our study confirmed the emerging data on the use of LDCT as a screening tool for lung neoplasm in individuals at risk. Due to the LDCT low rate of specificity complementary biomarkers are required to properly define patients at risk and to reduce the number of further radiological examinations.


Subject(s)
Adenocarcinoma/diagnostic imaging , Carcinoma, Squamous Cell/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Tomography, X-Ray Computed , Adenocarcinoma/epidemiology , Adenocarcinoma/surgery , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/surgery , Early Detection of Cancer/methods , Female , Follow-Up Studies , Humans , Incidence , Lung Neoplasms/epidemiology , Lung Neoplasms/surgery , Male , Middle Aged , Multidetector Computed Tomography/methods , Neoplasm Staging , Predictive Value of Tests , Prevalence , Retrospective Studies , Risk Factors , Rome , Sensitivity and Specificity , Smoking/adverse effects , Tomography, X-Ray Computed/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...